In malignant cells, NRF2 activation by G12Ci drugs contributes to their anti-cancer activity by promoting immune surveillance, while in immune cells, NRF2 activation promotes anti-cancer immunity by reducing oxidative stress, and repolarizing myeloid cells towards the anti-cancer M1 lineage. Here, NFE2L2 is linked to cancer.